CD109's involvement in cancers such as lung adenocarcinoma, glioblastomas, hepatocellular carcinomas, breast cancer, leukemia, and squamous cell carcinomas highlights its significant impact on immune responses and oncogenic process. The gene discussed is CD109; the disease is breast cancer.